Amgen’s BiTE for lung cancer backed for EU approval

Pharmaphorum

Amgen’s fast-growing bispecific T-cell engager Imdylltra should be cleared as a second-line therapy for small cell lung cancer, said the CHMP.

RegulatoryOncologyRead full story